An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Abivertinib-maleate (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 31 Jan 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.